LEADER 01366nam a22002411i 4500
001 991001970609707536
005 20040112142046.0
008 040407s1972    be a||||||||||||||||lat  
035   $ab12851140-39ule_inst
035   $aARCHE-083076$9ExL
040   $aDip.to Scienze Storiche$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l.
100 0 $aHenricus :$cGandavensis$0386648
245 13$aLa Lectura ordinaria super Sacram Scripturam, attribuée a Henri de Gand. Introductio generalis ad Sacram Scripturam. Introductio generalis ad Genesim. Expositio trium primorum capitulorum Genesis /$cédition critique par Raymond Macken ... 
260   $aLouvain :$bEditions universitaires,$c1972
300   $aXXXI, 290 p. :$b3 tav. ;$c25 cm
440  0$aAnalecta mediaevalia Namurcensia ;$v26
700 1 $aMacken, Raymond$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0164223
907   $a.b12851140$b02-04-14$c16-04-04
912   $a991001970609707536
945   $aLE009 Coll. VII, 26$g1$i2009000178984$lle009$o-$pE0.00$q-$rn$so  $t0$u0$v0$w0$x0$y.i13409219$z16-04-04
996   $aLectura ordinaria super Sacram Scripturam, attribuée a Henri de Gand. Introductio generalis ad Sacram Scripturam. Introductio generalis ad Genesim. Expositio trium primorum capitulorum Genesis$91448379
997   $aUNISALENTO
998   $ale009$b16-04-04$cm$da  $e-$flat$gbe $h3$i1

LEADER 02926nam  2200613   450 
001 9910808601903321
005 20230807201921.0
010   $a0-309-37326-3
010   $a0-309-37324-7
035   $a(CKB)3710000000513337
035   $a(EBL)4393789
035   $a(SSID)ssj0001692786
035   $a(PQKBManifestationID)16544493
035   $a(PQKBTitleCode)TC0001692786
035   $a(PQKBWorkID)15040543
035   $a(PQKB)25089884
035   $a(MiAaPQ)EBC4393789
035   $a(EXLCZ)993710000000513337
100   $a20160318h20152015  uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aFinancial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders $eworkshop summary /$fSheena M. Posey Norris [and three others], rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy
210  1$aWashington, District of Columbia :$cThe National Academies Press,$d2015.
210  4$d©2015
215   $a1 online resource (128 p.)
300   $aDescription based upon print version of record.
311   $a0-309-37323-9 
320   $aIncludes bibliographical references.
327   $aFrontMatter; Reviewers; Contents; 1 Introduction and Overview; 2 Improving Market Protection; 3 Strengthening the Regulatory Pathway; 4 Patient Benefit and Engagement; Appendix A: References; Appendix B: Workshop Agenda; Appendix C: Registered Attendees; Appendix D: Participant Biographies
606   $aPharmaceutical industry$xEconomic aspects
606   $aDrug development$xEconomic aspects
606   $aCentral nervous system$xDiseases$xEffect of drugs on
606   $aPublic-private sector cooperation
615  0$aPharmaceutical industry$xEconomic aspects.
615  0$aDrug development$xEconomic aspects.
615  0$aCentral nervous system$xDiseases$xEffect of drugs on.
615  0$aPublic-private sector cooperation.
676   $a615
700   $aNorris$b Sheena M. Posey$01643048
702   $aNorris$b Sheena M. Posey
712 02$aInstitute of Medicine (U.S.).$bForum on Neuroscience and Nervous System Disorders.
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy.
712 12$aFinancial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop)$f(2015 :$eWashington, D.C.),
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910808601903321
996   $aFinancial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders$94056464
997   $aUNINA